An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in Healthy Adult Male and Female Subjects Under Fasting Conditions
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Amlodipine/losartan (Primary) ; Amlodipine; Losartan
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 21 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2013 Planned number of patients changed from 102 to 204 as reported by ClinicalTrials.gov.
- 31 May 2013 Planned End Date changed from 31 May 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.